Illumina shares hold the 200 day line, analysts stay at Hold

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-29, 09:40.

Illumina Inc. (US4523271090) trades on Nasdaq as analysts keep a cautious view on the shares. MarketBeat said on June 29 that 19 research firms covering the life-sciences group give the stock a consensus rating of Hold according to MarketBeat.

Consensus stays cautious

The same MarketBeat update said the shares opened at $176.55 on Monday and stood close to the 12-month high of $182.84. It also put the 50-day moving average at $149.62 and the 200-day line at $137.73.

That gap leaves the Nasdaq listing above both moving averages, a technical backdrop that stays visible for traders. MarketBeat also said Illumina last reported quarterly earnings on April 30, with EPS of $1.15 versus a $1.05 consensus estimate.

How the week starts

Monday trading puts the analyst picture and the chart setup side by side. The share price reference in the MarketBeat note gives the session a concrete anchor on Nasdaq, while the consensus rating keeps the tone restrained.

For peer context, large-cap life-science names such as Thermo Fisher and Danaher remain the sector reference points for U.S. investors. That comparison matters because Illumina's valuation and trading range often get read against broader tools-and-diagnostics multiples.

Sequencing remains the core

Illumina's business still centers on next-generation sequencing systems and consumables used in genomics research and clinical workflows. The company says its platform spans sequencing instruments, reagents and related services on its corporate site Illumina's investor and product materials.

Nasdaq price reference

The Illumina shares (US4523271090) trade on Nasdaq at $176.55 as of 2026-06-26, 16:00, in the MarketBeat price reference.

Disclaimer: This article is for information only and does not constitute investment advice.